Abstract:In effort s to achieve minimal systemic toxicity and high tumor delivery efficiencies in cancer therapy, various nanomedicine formulations having stealth polymer coatings have been developed for minimizing immune cell uptake and off-target macrophage phagocyte system (MPS) organ accumulation. Despite an initial reduction in immune cell uptake, stealth nanoparticles still initiate an antibody immune response. This response acts on subsequent administrations in treatment regimens resulting in accelerated blood clearance of particles into MPS organs, particularly the liver, where they are retained for prolonged periods. Consequently, doses after the first administration in treatment regimens have diminished tumor accumulation and increased MPS toxicity. Here, we present a strategy reducing antibody responses to each dose in a treatment regimen by alternating between polyethylene-glycol and polymethyloxazoline polymers as the nanoparticle coating between administrations. In a weekly dosing regimen, we find that the first dose of particles having either coating display similar favorable pharmacokinetics and biodistributions, thus allowing the polymers to be used interchangeably. However, when maintaining the same coating in subsequent administrations, we find that particles are in circulation at the height of the antibody immune response resulting in 50-60% decreases of circulation half-lives and tumor accumulation along with 50% increases in liver accumulation. By alternating the polymers used in the nanoparticle coating between administrations, we find each dose maintains favorable in vivo behaviors at the height of the antibody immune response to the previous administration. Furthermore, our strategy increases the clearance of particles uptaken by macrophages and hepatocytes, resulting in marked decreases in hepatotoxicity. Statement of significance While nanoparticles with coatings consisting of stealth polymers can minimize immune cell uptake, they still initiate antibody immune responses leading to rapid blood clearance and MPS sequestration of subsequent administrations within a treatment regimen. We demonstrate that by alternating PEG and PMOZ polymer coatings between weekly administrations, the antibody immune response acting on each administration is minimal, and the favorable in vivo behaviors observed with the first administration is maintained in subsequent administrations. In this case, greater tumor accumulation is achieved while curtailing excessive MPS organ accumulation and toxicity throughout a nanomedicine treatment. We envision our strategy will benefit clinical trials where frequent administrations of therapeutics are required or in sequential deliveries of prognostic and therapeutic agents. (c) 2021 Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Sulfoxide‐Containing Polymer‐Coated Nanoparticles Demonstrate Minimal Protein Fouling and Improved Blood Circulation

Reducing Non-Specific Binding and Uptake of Nanoparticles and Improving Cell Targeting with an Antifouling PEO-b-PγMPS Copolymer Coating

Biocompatible Polysiloxane-Containing Diblock Copolymer Peo-B-P Gamma Mps for Coating Magnetic Nanoparticles

Stimuli-Responsive Sulfoxide Polymer–Protein Conjugates with Improved Pharmacokinetics and Tumor Delivery

New-Type Sulphonated Polymer Surfaces for Improving Blood Compatibility

Sulfoxide-containing Polymers Conjugated Prodrug Micelles with Enhanced Anticancer Activity and Reduced Intestinal Toxicity.

Biopolymer Coating for Particle Surface Engineering and Their Biomedical Applications

Biodegradable zwitterionic polymer membrane coating endowing nanoparticles with ultra-long circulation and enhanced tumor photothermal therapy

Enhancing Physicochemical Properties and Biocompatibility of Hollow Porous Iron Oxide Nanoparticles through Polymer-Based Surface Modifications

PEG- b -AGE Polymer Coated Magnetic Nanoparticle Probes with Facile Functionalization and Anti-fouling Properties for Reducing Non-specific Uptake and Improving Biomarker Targeting.

Preventing corona effects: multi-phosphonic acid poly(ethylene glycol) copolymers for stable stealth iron oxide nanoparticles

Alternating Stealth Polymer Coatings Between Administrations Minimizes Toxic and Antibody Immune Responses Towards Nanomedicine Treatment Regimens.

Mussel-Inspired Multifunctional Polyethylene Glycol Nanoparticle Interfaces

Efficacy and Safety of a Novel Nano-Porous Polymer-Free Sirolimus-Eluting Stent in Pigs.

Stealth Coating of Nanoparticles in Drug-Delivery Systems

Zwitterionic Polymer Coating of Sulfur Dioxide‐Releasing Nanosystem Augments Tumor Accumulation and Treatment Efficacy

Passivation protein-adhesion platform promoting stent reendothelialization using two-electron-assisted oxidation of polyphenols

Neutrophil Extracellular Traps-Inhibiting and Fouling-Resistant Polysulfoxides Potently Prevent Postoperative Adhesion, Tumor Recurrence, and Metastasis

Lubricant-entrenched Slippery Surface-based Nanocarriers to Avoid Macrophage Uptake and Improve Drug Utilization

PEG Branched Polymer for Functionalization of Nanomaterials with Ultralong Blood Circulation

Effective Pegylation of Iron Oxide Nanoparticles for High Performance in Vivo Cancer Imaging